{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:34:38Z","timestamp":1762079678305,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.carrev.2019.01.012","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:43:23Z","timestamp":1547199803000},"page":"177-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval?"],"prefix":"10.1016","volume":"20","author":[{"given":"Lillian","family":"Benck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2019.01.012_bb0005","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/euhj.2001.2706","article-title":"The problem of chronic refractory angina. Report from the ESC joint study group on the treatment of refractory angina","volume":"23","author":"Mannheimer","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2019.01.012_bb0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrcardio.2013.200","article-title":"Treatment of refractory angina in patients not suitable for revascularization","volume":"11","author":"Henry","year":"2013","journal-title":"Nat Rev Cardiol"},{"year":"2010","series-title":"Cardiovascular disability: updating the social security listings","author":"Institute of Medicine Committee on Social Security Cardiovascular Disability C","key":"10.1016\/j.carrev.2019.01.012_bb0015"},{"key":"10.1016\/j.carrev.2019.01.012_bb0020","first-page":"219","article-title":"Intramyocardial autologous CD34+ cell therapy for refractory angina: a meta-analysis of randomized controlled trials","author":"Velagapudi","year":"2019","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.carrev.2019.01.012_bb0025","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0002-9149(99)00387-2","article-title":"Direct myocardial revascularization and angiogenesis\u2013how many patients might be eligible?","volume":"84","author":"Mukherjee","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2019.01.012_bb0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heart.87.2.140","article-title":"Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population","volume":"87","author":"Brorsson","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2019.01.012_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejcnurse.2006.01.003","article-title":"Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization: results from the euro heart survey on coronary revascularization","volume":"5","author":"Lenzen","year":"2006","journal-title":"Eur J Cardiovasc Nurs"},{"key":"10.1016\/j.carrev.2019.01.012_bb0040","first-page":"886","article-title":"Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality","volume":"75","author":"Williams","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2019.01.012_bb0045","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke Statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2019.01.012_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176257","article-title":"Clinical presentation and management of stable coronary artery disease in Austria","volume":"12","author":"Pichlhofer","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.carrev.2019.01.012_bb0055","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","article-title":"The prevalence of weekly angina among patients with chronic stable angina in primary care practices. The coronary artery disease in general practice (CADENCE) study","volume":"169","author":"Beltrane","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.carrev.2019.01.012_bb0060","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.recesp.2012.03.011","article-title":"AVANCE study researchers. Stable angina in Spain and its impact on quality of life. The AVANCE registry","volume":"65","author":"Borr\u00e1s","year":"2012","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.carrev.2019.01.012_bb0065","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1161\/CIRCULATIONAHA.106.687376","article-title":"Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina. A phase I\/IIa double-blind, randomized controlled trial","volume":"115","author":"Losordo","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2019.01.012_bb0070","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.carrev.2019.01.012_bb0075","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3727\/096368916X691484","article-title":"Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study","volume":"25","author":"Henry","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.carrev.2019.01.012_bb0080","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ahj.2013.03.003","article-title":"A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study","volume":"165","author":"Povsic","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2019.01.012_bb0085","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW trial: efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina","volume":"9","author":"Povsic","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.carrev.2019.01.012_bb0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1067\/mhj.2001.119136","article-title":"Advanced coronary artery disease: appropriate end points for trials of novel therapies","volume":"142","author":"Kandzari","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2019.01.012_bb0095","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ahj.2009.10.013","article-title":"Long-term morbidity and mortality among medically managed patients with angina and multivessel coronary artery disease","volume":"158","author":"Cavender","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.carrev.2019.01.012_bb0100","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2019.01.012_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001287","article-title":"Predictors of long-term clinical endpoints in patients with refractory angina","volume":"4","author":"Povsic","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.carrev.2019.01.012_bb0110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(03)12111-3","article-title":"Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation","volume":"361","author":"Tse","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2019.01.012_bb0115","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1161\/CIRCULATIONAHA.106.644518","article-title":"CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells","volume":"114","author":"Kawamoto","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2019.01.012_bb0120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2019.01.012_bb0125","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehx764","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","volume":"39","author":"Henry","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919300429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838919300429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:15:31Z","timestamp":1761560131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838919300429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1553838919300429"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2019.01.012","relation":{},"ISSN":["1553-8389"],"issn-type":[{"type":"print","value":"1553-8389"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval?","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2019.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}